Results 111 to 120 of about 1,996,956 (313)

THE EFFECT OF MARKETING COOPERATIVES ON COST-REDUCING PROCESS INNOVATION ACTIVITY [PDF]

open access: yes
This paper examines the market and welfare effects of cooperative involvement in cost-reducing process innovation activity in the context of a mixed oligopsony where an open-membership marketing co-op competes with an IOF.
Drivas, Kyriakos   +1 more
core   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

LEGAL SUPPORT TO INNOVATIVE ACTIVITIES [PDF]

open access: yesЭкономика региона, 2009
The whole system of economy regulation, all the institutes of economic law, especially those which regulate investment activity should promote innovative activities. The economic policy and legislation that provides it should be stable enough.
openaire   +1 more source

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

open access: yesMolecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor   +2 more
wiley   +1 more source

Innovative strategies for active learning

open access: yesÎnvăţare activă pentru dezvoltare durabilă : Conferinţă ştiinţifică internaţională : Eveniment online, 15 noiembrie 2024 = Active learning for sustainable development : International Scientific Conference : Online event, November 15, 2024 : Conference proceedings
In a modern educational context, active learning has become a central element in the development of critical skills necessary to adapt to the dynamics of the labor market and a knowledge-based society. This article explores various innovative strategies in active learning, such as problem-based learning (PBL), project-based learning (PjBL ...
openaire   +2 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Russian Companies do Innovate [PDF]

open access: yes
Innovation is a vital process for organizations and countries in order to be able to evolve and have a competitive position in the international markets.
Alexey PRAZDNICHNYKH, Kari LIUHTO
core  

Pharmaceutical M&A Activity: Effects on Prices, Innovation, and Competition [PDF]

open access: yes, 2017
The rise of blockbuster pharmaceutical acquisitions has prompted fears that unprecedented market concentration will weaken competition. Two of the most prominent concerns focus on the upstream and downstream ends of the pharmaceutical industry: (1) the ...
Mitchell, Will   +3 more
core   +1 more source

Molecular cancer prevention: Intercepting disease

open access: yesMolecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy